Distribution and pharmacokinetics of etamicastat and its N-acetylated metabolite (BIA 5-961) in dog and monkey

References

• Beliaev A, Learmonth DA, Soares-da-Silva P. (2006). Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase. J Med Chem 49:1191–7
   PubMed Web of Science ®Google Scholar
• Bonifácio MJ, Igreja B, Wright L, Soares-da-Silva P. (2009). Kinetic studies on the inhibition of dopamine-β-hydroxylase by BIA 5-453. pA2 online 7:050P (abstract)
   Google Scholar
• Bonifácio MJ, Sousa F, Igreja B, et al. (2012). BIA 5-1058 is a new noncompetitive dopamine-β-hydroxylase inhibitor. pA2 online 10:279P
   Google Scholar
• Chapelsky MC, Martin DE, Tenero DM, et al. (1998). A dose proportionality study of eprosartan in healthy male volunteers. J Clin Pharmacol 38:34–9
   PubMed Web of Science ®Google Scholar
• Collins JM. (2001). Inter-species differences in drug properties. Chem Biol Interact 134:237–42
   PubMed Web of Science ®Google Scholar
• Gao W, Johnston JS, Miller DD, Dalton JT. (2006). Interspecies differences in pharmacokinetics and metabolism of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of N-acetyltransferase. Drug Metab Dispos 34:254–60
   PubMed Web of Science ®Google Scholar
• Glinsukon T, Benjamin T, Grantham PH, et al. (1975). Enzymic N-acetylation of 2,4-toluenediamine by liver cytosols from various species. Xenobiotica 5:475–83
   PubMed Web of Science ®Google Scholar
• Hein DW, Doll MA, Fretland AJ, et al. (2000a). Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9:29–42
   PubMed Web of Science ®Google Scholar
• Hein DW, McQueen CA, Grant DM, et al. (2000b). Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab Dispos 28:1425–32
   PubMed Web of Science ®Google Scholar
• Igreja B, Pires NM, Bonifacio MJ, et al. (2015). Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat. Hypertens Res 38:30–8
   PubMed Web of Science ®Google Scholar
• Igreja B, Pires NM, Wright LC, Soares-da-Silva P. (2012). Antihypertensive effect of BIA 5-1058 a new selective peripheral dopamine β-hydroxylase inhibitor. Hypertension 60 (3 Supplement):A291
   Google Scholar
• Igreja B, Pires NM, Wright LC, Soares-da-Silva P. (2013). BIA 5-1058, beyond blood pressure, improves cardiometabolism and decrease end-organ damage. Hypertension 62 (3 Supplement):A532
   Google Scholar
• Lin JH. (1994). Dose-dependent pharmacokinetics: experimental observations and theoretical considerations. Biopharm Drug Dispos 15:1–31
   PubMed Web of Science ®Google Scholar
• Loureiro AI, Fernandes-Lopes C, Bonifacio MJ, et al. (2013). N-acetylation of etamicastat, a reversible dopamine-beta-hydroxylase inhibitor. Drug Metab Dispos 41:2081–6
   PubMed Web of Science ®Google Scholar
• Loureiro AI, Joao Bonifacio M, Fernandes-Lopes C, et al. (2014a). Etamicastat, a new dopamine-β-hydroxylase inhibitor, pharmacodynamics and metabolism in rat. Eur J Pharmacol 740:285–94
   PubMed Web of Science ®Google Scholar
• Loureiro AI, Rocha JF, Fernandes-Lopes C, et al. (2014b). Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine beta-hydroxylase inhibitor. Br J Clin Pharmacol 77:1017–26
   PubMed Web of Science ®Google Scholar
• Ludden TM. (1991). Nonlinear pharmacokinetics: clinical Implications. Clin Pharmacokinet 20:429–46
   PubMed Web of Science ®Google Scholar
• Nagaya Y, Takenaka O, Kusano K, Yoshimura T. (2013). Species difference in the mechanism of nonlinear pharmacokinetics of E2074, a novel sodium channel inhibitor, in rats, dogs, and monkeys. Drug Metab Dispos 41:1004–11
   PubMed Web of Science ®Google Scholar
• Nunes T, Rocha JF, Vaz-da-Silva M, et al. (2010). Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D 10:225–42
   PubMedGoogle Scholar
• Nunes T, Rocha JF, Vaz-da-Silva M, et al. (2011). Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. Clin Ther 33:776–91
   PubMed Web of Science ®Google Scholar
• Philip PA, Rogers HJ, Millis RR, et al. (1987). Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur J Cancer Clin Oncol 23:1701–6
   PubMedGoogle Scholar
• Rocha JF, Vaz-da-Silva M, Nunes T, et al. (2012). Single-Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5-453), a New Dopamine {beta}-Hydroxylase Inhibitor, in Healthy Subjects. J Clin Pharmacol 52:156–70
   PubMed Web of Science ®Google Scholar
• Roller S, Cui D, Laspina C, et al. (2009). Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences. Xenobiotica 39:33–45
   PubMed Web of Science ®Google Scholar
• Sharer JE, Shipley LA, Vandenbranden MR, et al. (1995). Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 23:1231–41
   PubMed Web of Science ®Google Scholar
• Stanley LA, Sim E. (2008). Update on the pharmacogenetics of NATs: structural considerations. Pharmacogenomics 9:1673–93
   PubMed Web of Science ®Google Scholar
• Su TZ, Feng MR, Weber ML. (2005). Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther 313:1406–15
   PubMed Web of Science ®Google Scholar
• Sugimoto T, Furuta S, Kawamata H, et al. (1999). Pharmacokinetics of a new histamine H2-receptor antagonist, Z-300, in rat and dog. Xenobiotica 29:425–33
   PubMed Web of Science ®Google Scholar
• Vaz-da-Silva M, Nunes T, Rocha JF, et al. (2011). Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). Drugs R D 11:127–36
   PubMedGoogle Scholar
• Walraven JM, Zang Y, Trent JO, Hein DW. (2008). Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr Drug Metab 9:471–86
   PubMed Web of Science ®Google Scholar
• Winter HR, Unadkat JD. (2005). Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos 33:969–76
   PubMed Web of Science ®Google Scholar
• Wright L, Soares-da-Silva P. (2008). Long-term benefits of the selective peripheral dopamine-β-hydroxylase inhibitor BIA 5-453 in heart failure. pA2 online 6:088P (abstract)
   Google Scholar